November 3, 2022

 

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, NE

Washington, D.C. 20549

Attention: Ada D. Sarmento

 

	Re:	NeuroBo Pharmaceuticals, Inc.
		Registration Statement on Form S-1
		File No. 333-267482
		Acceleration Request

 

	Requested Date:	November 4, 2022
	Requested Time:	9:00 A.M. Eastern Time

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-1 (File No. 333-267482) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence, Samuel Katz and Garrett Packer of Honigman LLP, counsel to the Company, to make such request on its behalf.

 

Please confirm the effectiveness of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702, Samuel Katz of Honigman LLP by telephone at (313) 465-8137 or Garrett Packer of Honigman LLP by telephone at (313) 465-8090.

 

[Signature page follows]

 

****

 

 

	Sincerely,
	NeuroBo Pharmaceuticals, Inc.
	/s/ Gil Price
	Gil Price, M.D.
	President and Chief Executive Officer

 

	cc:	Phillip Torrence, Honigman LLP
		Samuel Katz, Honigman LLP
		Garrett Packer, Honigman LLP